Related Experiment Video
Updated: Jun 21, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Therapy: Targeted but not trouble-free: efalizumab and PML
Eamonn S Molloy1, Leonard H Calabrese
1Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH 44195, USA. molloye@ccf.org
Abstract:
In April 2009, efalizumab was withdrawn from the market for the treatment of psoriasis after reports emerged of an association between long-term therapy and the development of progressive multifocal leukoencephalopathy (PML). This event highlights an urgent need for greater awareness and research into the screening, diagnosis and treatment of this potentially fatal disease in patients undergoing immunosuppressive therapy for chronic inflammatory disorders.
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Rocky Mountain Spotted Fever
Psychosis: Goals of Pharmacotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF